How to buy Moderna (MRNA) shares in Australia
Learn how to easily invest in Moderna shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
In mid November, US drugmaker Moderna announced its experimental COVID-19 vaccine was 94.5% effective in preventing the virus. The news comes just a week after Pfizer's vaccine revealed a 90% accuracy rate.
Moderna (MRNA) is a US pharmaceutical and biotechnology company. The company focuses on messenger RNA (mRNA) technology and was among the first to develop a vaccination against COVID-19. Moderna was founded in 2010 and its headquarters are in Cambridge, Massachusetts in the USA.
How to buy shares in Moderna
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Moderna. Find the share by name or ticker symbol: MRNA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moderna reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$454.6, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Moderna, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Moderna. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Moderna stock price (NASDAQ:MRNA)Use our graph to track the performance of MRNA stocks over time.
Moderna shares at a glance
|52-week range||US$65.49 - US$497.49|
|50-day moving average||US$413.6259|
|200-day moving average||US$253.2295|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$8.464|
Where to buy Moderna stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Moderna stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Moderna shares?Before you consider Moderna, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Moderna price performance over time
|1 week (2021-09-16)||-2.39%|
|1 month (2021-08-26)||7.45%|
|3 months (2021-06-25)||95.57%|
|6 months (2021-03-26)||222.73%|
|1 year (2020-09-25)||519.17%|
|2 years (2019-09-26)||2,532.44%|
Stocks similar to Moderna
Is Moderna under- or over-valued?
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's P/E ratio
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Moderna shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.9 billion (£2.9 billion).
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$7 billion|
|Operating margin TTM||54.39%|
|Gross profit TTM||US$-574,877,000|
|Return on assets TTM||24.3%|
|Return on equity TTM||72.43%|
|Market capitalisation||US$173.6 billion|
TTM: trailing 12 months
Shorting Moderna shares
There are currently 15.4 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 18.1% down from 18.8 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR)
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 24.4 million). Moderna's SIR currently stands at 0.63. In other words for every 100,000 Moderna shares traded daily on the market, roughly 630 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 30 shares are currently held short) or 0.04% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
Moderna share dividends
We're not expecting Moderna to pay a dividend over the next 12 months.
Moderna share price volatility
Over the last 12 months, Moderna's shares have ranged in value from as little as US$65.49 up to US$497.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.4792. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna in the news
COVID-19 vaccine boosters could mean billions in profit for drugmakers
Is It Too Late to Buy Moderna Stock?
COVID-19 vaccine boosters could mean billions for drugmakers
Frequently asked questions
More guides on Finder
How to buy Incannex Healthcare (IHL) shares
Steps to owning and managing Incannex Healthcare from Australia.
How to buy The Scotts Miracle-Gro Company (SMG) shares in Australia
Steps to owning and managing Scotts Miracle Go shares from Australia.
Why is the Qantas share price flying higher?
Shares in the national carrier are up 30% over the last 12 months.
How to buy Frax Share (FXS) in Australia
This guide will show you step-by-step instructions on how to buy the Frax Share (FXS) token as well as a list of exchanges you can trade it on.
How to buy ShareToken (SHR) in Australia
This guide will show you step-by-step instructions on how to buy the ShareToken (SHR) token as well as a list of exchanges you can trade it on.
How to buy Rubicon Water (RWL) shares
Steps to owning and managing Rubicon Water shares.
How to buy Endeavour Group (EDV) shares
Steps to owning and managing Endeavour Group Limited shares from Australia.
How to buy Betashares Legg Mason Emerging Markets Fund Managed Fund units | A$7
Steps to owning and managing BetaShares Legg Mason Emerging Markets Fund (Managed Fund) ETF units.
How to buy Einvest Future Impact Small Caps Fund Managed Fund units | A$6.03
Steps to owning and managing eInvest Future Impact Small Caps Fund (Managed Fund) ETF units.
How to buy Vaneck Vectors Msci International Value Etf units | A$22.2
Steps to owning and managing VanEck Vectors MSCI International Value ETF units.
Ask an Expert